Short-Term Continuous Subcutaneous Insulin Infusion Combined with Insulin Sensitizers Rosiglitazone, Metformin, or Antioxidant α-Lipoic Acid in Patients with Newly Diagnosed Type 2 Diabetes Mellitus

BACKGROUND: Short-term continuous subcutaneous insulin infusion (CSII) in patients with newly diagnosed type 2 diabetes has been proved effective in improving metabolic control and β-cell function, thus inducing long-term drug-free remission. A randomized controlled trial was conducted to investigat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Huang, Zhimin, Wan, Xuesi, Liu, Juan, Deng, Wanping, Chen, Ailing, Liu, Liehua, Liu, Jianbin, Wei, Guohong, Li, Hai, Fang, Donghong, Li, Yanbing
Format: Artigo
Sprache:Inglês
Veröffentlicht: Mary Ann Liebert, Inc. 2013
Schlagworte:
Original Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3781121/
https://ncbi.nlm.nih.gov/pubmed/23991629
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/dia.2013.0013
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge